Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advancements review identified that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://rudyc654rtk5.wonderkingwiki.com/user